Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder involving an extensive loss of motoneurons. Aberrant excitability of motoneurons has been implicated in the pathogenesis of selective motoneuronal death in ALS. D-Serine, an endogenous coagonist of N-methyl-D-aspartate receptors, exacerbates motoneuronal death and is increased both in patients with sporadic/ familial ALS and in a G93A-SOD1 mouse model of ALS (mSOD1 mouse). More recently, a unique mutation in the D-amino acid oxidase (DAO) gene, encoding a D-serine degrading enzyme, was reported to be associated with classical familial ALS. However, whether DAO affects the motoneuronal phenotype and D-serine increase in ALS remains uncertain. Here, we show that genetic inactivation of DAO in mice reduces the number and size of lower motoneurons with axonal degeneration, and that suppressed DAO activity in reactive astrocytes in the reticulospinal tract, one of the major inputs to the lower motoneurons, predominantly contributes to the D-serine increase in the mSOD1 mouse. The DAO inactivity resulted from expressional down-regulation, which was reversed by inhibitors of a glutamate receptor and MEK, but not by those of inflammatory stimuli. Our findings provide evidence that DAO has a pivotal role in motoneuron degeneration through D-serine regulation and that inactivity of DAO is a common feature between the mSOD1 ALS mouse model and the mutant DAO-associated familial ALS. The therapeutic benefit of reducing D-serine or controlling DAO activity in ALS should be tested in future studies.
A myotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by selective loss of motoneurons in the spinal cord and brain leading to fatal paralysis. Approximately 90% of all cases are sporadic, and the remaining cases are inherited. Of inherited cases, 20% are associated with mutations in superoxide dismutase 1 (SOD1), and 10% involves 43-kDa transactivation response DNA-binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS). Despite extensive studies of previously identified ALS-causing genes, the mechanism underlying the selective motoneuronal loss in ALS remains uncertain. Given that the mechanism is at least, in part, common between sporadic and familial ALS, identification of the common pathology is a clue to conquering ALS. Among numerous etiological hypotheses, motoneuronal vulnerability to excitotoxicity is one of the most intensely investigated targets for the treatment of ALS because it is observed in both sporadic and familial ALS with SOD1 mutations (1, 2) . For motoneurons, glutamate is the main excitatory transmitter, and excessive motoneuron excitability by glutamate through ionotropic glutamate receptors has been demonstrated.
The N-methyl-D-aspartate (NMDA) receptor (NMDAR) is a subtype of the ionotropic glutamate receptors and exhibits relatively higher permeability to the calcium ion (Ca 2+ ) than non-NMDARs, which links it to a variety of physiological and pathological processes. Unlike non-NMDARs, glutamate does not activate the NMDARs unless a coagonist binding site is occupied. D-Serine, an unusual D-amino acid found in mammalian brain, is a physiological ligand of the coagonist site of the NMDARs (3, 4) ; hence, it is pivotal in determining excitability of glutamatergic neurons. D-Serine is endogenously converted from L-serine by serine racemase (SRR) (5) and exists at a high level in the forebrain, where it has a critical role in long-term potentiation (6) and is required for memory formation (6) . D-Serine is also involved in NMDAR-mediated neurotoxicity, a process that plays a pathophysiological role in stroke and neurodegenerative diseases (7) (8) (9) . We previously reported that D-serine is increased in the spinal cord in both patients with sporadic/familial ALS and in a G93A-SOD1 mouse model of ALS (mSOD1 mouse) (10) . D-Serine is progressively increased with expressional elevation of SRR caused by glial activation (10) . Intriguingly, a point mutation that diminishes enzyme activity in D-amino acid oxidase (DAO), a D-serine degrading enzyme, is associated with familial ALS (11) . However, whether DAO is related to D-serine increase in ALS, or DAO inactivity is relevant to motoneuronal degeneration in vivo, remains uncertain. In this study, we found that DAO activity is strikingly suppressed in the reticulospinal tract of mSOD1 mice, which plays a central role in D-serine increase in mSOD1 mice, and that loss of DAO activity results in motoneuron degeneration.
Results DAO is highly expressed in mammalian CNS, liver, and kidney and catalyzes the oxidative deamination of D-amino acids. ddY/ DAO − mice, found in outbred ddY mice (12) , lack DAO activity because of a natural point mutation (G181R) (13) and show abnormal locomotor behavior related to enhanced NMDAR function (14) . Because hypofunction of the NMDAR and genetic association of DAO have been implicated in schizophrenia, most studies using ddY/DAO − mice have focused on a therapeutic approach to schizophrenia through D-serine increase. No phenotypic analysis of spinal motoneurons in the mice, however, has yet been conducted. To study whether inactivation of DAO affects the motoneuronal phenotype in vivo, ddY/DAO − mice were backcrossed with C57BL/6J and maintained as homozygotes ( B6 DAO −/− mice). The B6 DAO −/− mice developed an abnormal limb reflex characterized by retraction of hindlimbs toward the trunk when they were lifted up by their tails, whereas C57BL/6J mice showed normal extension of the hindlimbs (Fig. 1A) . Motoneurons of the lumbar ventral horn in B6 DAO −/− mice exhibited morphology of degeneration (Fig. 1B) , including the reduction in number by 24% ( Fig. 1C and Fig. S1 A-C) and in size of their somata by 15% on average ( Fig. 1D and Fig. S1D ) compared with age-matched C57BL/6J mice. In aged B6 DAO −/− mice, ubiquitin-positive aggregations were observed in the ventral neurons ( Fig. 1 E and F) , and the ubiquitin-immunoreactive smear was increased in the immunoblotting of spinal cords (Fig.  1G ), but no expressional or localization changes of NMDARs were detected except for localization shift of NR2A ( Fig. S1 E and F). Furthermore, inactivation of DAO triggers axonal degeneration with muscle atrophy in aged mice ( Fig. 1 H and I and Fig. S1G ). These findings demonstrate that DAO activity influences the motoneuronal phenotype.
To elucidate the pathophysiological significance of DAO in ALS, we visualized DAO activity in cryostat sections by modifying an enzyme histochemical (EHC) technique for vibratome sections (15) . EHC is based on oxidation of diaminobenzidine with peroxidase by using D-proline as a substrate of DAO. Intense enzymatic reactivity was observed in the cerebellum, and relatively weak reactivity was in the pons, medulla oblongata, and spinal cord, whereas there was no signal at all in the forebrain region ( Fig. S2 A and B) . The specificity of the EHC was verified by using L-proline as a substrate or tissue sections from B6 DAO −/− mice (Fig. S2C ). In the spinal cord, DAO was mainly distributed in the anterior columns, where motor axons descend from upper neurons, and in lamina VIII and IX of ventral spinal gray matter ( Fig. 2A) . This distribution pattern suggested a correlation between DAO activity and the motor tract. Because D-serine is essential for the neurotoxicity through NMDARs (7), DAO has been thought to associate with diseases that involve NMDAR malfunction. A R199W mutation in DAO found in patients with familial ALS resulted in dramatic deactivation of DAO ( Fig. S3 A and B) and motoneuronal death in vitro (11) . In mSOD1 mice (16) , the most studied ALS animal model, DAO activity was significantly decreased compared with that in agematched wild-type mice (control mice) especially in the ventral part of lumbar spinal cords ( Fig. 2A) (Fig. 2B) . This suppressed activity of DAO resulted from marked reduction of DAO protein expression in Western blotting of spinal cords of mSOD1 mice at the end stage, although significant reduction was not observed at the onset ( Fig. 2C and Fig. S2 D and E) .
Using FITC-conjugated tyramide, which reacts sensitively with peroxidase and enhances the sensitivity of EHC (Fig. S2 A and  B) , we performed double staining of DAO activity and glial fibrillary acidic protein (GFAP; an astrocytic marker), Iba1 (a microglial marker), or nonphosphorylated neurofilament H (npNFH, a marker for motoneuron) and found that DAO activity was located in a portion of quiescent astrocytes (Fig. 2 D-F and Fig. S2 F and G) , but not in microglia (Fig. 2G) or somata/ axons of motoneurons ( Fig. 2 H and I) . Pyramidal neurons such as Purkinje cells in the cerebellum and large neurons in the brain-stem reticular formation did not exhibit any activity of DAO ( Fig. S2 H and I) . Of note is that in mSOD1 mice, DAO activity was severely suppressed in reactive astrocytes ( Fig. 2 D and E, Right). To further observe the DAO activity in the upper motor tract in mSOD1 mice, sagittal sections were stained with EHC enhanced with FITC-tyramide. DAO activity was strikingly decreased in reactive astrocytes in brainstem reticular formation of mSOD1 mice compared with control mice ( in rodents (17) . In contrast to the brainstem and spinal cord, DAO activities in the tissues rich in DAO, the cerebellum and kidney, were not altered in mSOD1 mice ( Fig. S2J) , suggesting that the DAO inactivation in the reticulospinal tract was not caused simply by expression of G93A-SOD1, but was affected by ALS pathophysiology. Does the suppression of DAO activity affect D-serine levels? The net amount of D-serine is controlled in balance with synthesis and degradation. To evaluate each contribution, we measured the amount of D-/L-serine with a 2D-HPLC system, a highly selective and sensitive method ( Fig. S4 and Materials and Methods) (18, 19 ). The D-serine level in the spinal cord is negatively correlated with the activity of DAO (Fig. 3A) , suggesting that DAO crucially determines the D-serine level in this region. In the spinal cords of mSOD1 mice, D-serine was progressively increased (Fig. 3B) (10) , whereas no significant alteration of D-serine was detected in those of control mice (Fig. 3B ) or in the cortices between mSOD1 and control mice (Fig. S4 F-H) . Although the L-serine level was also increased (Fig. 3C ) consistent with a previous report (20) , the D-/L-serine ratio was still higher in mSOD1 mice than in control mice (Fig. 3D) . The elevated D-/L-ratio implies three possibilities: D-serine synthesis was increased, D-serine degradation was decreased, or both. To evaluate the contribution of synthesis and degradation to the D-serine increase, we generated mSOD1 mice lacking DAO activity ( B6 DAO (18, 19, 21) , as a control D-amino acid that is not metabolized by DAO. Genetic inactivation of DAO markedly increased the D-alanine level, whereas D-aspartate was not affected at all (Fig. S6A) . In contrast to D-serine, the levels of D-alanine and D-aspartate in the spinal cord of mSOD1 mice did not differ significantly from control ( Fig. S6 A-C) . We speculate that the D-alanine level was not increased in mSOD1 mice because it is a better substrate of DAO than D-serine (22) : D-serine was not fully degraded in heterozygotes ( B6 DAO +/− ) with half the DAO activity of control mice ( B6 DAO +/+ ) ( Fig. 2B and Fig. S6A ), whereas D-alanine in B6 DAO +/− mice was kept as low as that in B6 DAO +/+ mice (Fig. S6A) . Therefore, DAO inactivation increased solely D-serine because DAO activity was half, but not fully, inactivated in mSOD1 mice (Fig. 2B) .
Is D-serine also increased in other neurodegenerative diseases? We examined mouse models for ALS/frontotemporal lobar degeneration (FTLD), sporadic Parkinson's disease, and familial Alzheimer's disease: A315T-TDP-43 transgenic mice (mTDP-43 mice), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, and Tg2576 mice, respectively. D-Serine was specifically increased in mSOD1 mice, but not in other principal animal models for neurodegenerative diseases (Fig. S7A) . Although the mTDP-43 mice exhibit a motoneuronal phenotype as do the mSOD1 mice (23) , DAO activity in mTDP-43 mice was almost identical to that in control mice (Fig. S7 B  and C) . Reactive astrocytes, also observed in mTDP-43 mice (23), did not show DAO activity, but a portion of quiescent astrocytes were supposed to retain the normal level of DAO activity in spinal cords of mTDP-43 mice (Fig. S7D) . These results suggested that the pathological significance of DAO was different between models of ALS and ALS/FTLD. What decreased DAO protein level in mSOD1 mice? The mRNA level of DAO was suppressed even at the preonset stage of mSOD1 mice and continued to decrease over the course of the disease (Fig. 4A) . Because DAO activity was suppressed in reactive astrocytes (Fig. 2 D, E , and K), we speculated that some extracellular soluble factor, such as proinflammatory cytokines or glutamate (24) , influenced DAO expression in mSOD1 mice. Incubation of primary cultured glia with spinal cord lysates of the end-staged mSOD1 mouse reduced mRNA expression of DAO in glia by 34% compared with that of the control mouse (Fig. 4B) . Among specific inhibitors for principal intracellular signaling pathways [PD98059: for MAPK/extracellular signalregulated kinase (MEK) 1, SP600125: for c-Jun N-terminal kinase, SB203580: for p38, wortmannin: for phosphatidylinositol-3 kinase, AG490: for Janus kinase 2, caffeic acid phenethyl ester (CAPE): for NF-κB; ref. 25] , only PD98059 recovered the downregulation of DAO caused by the mSOD1 lysate (Fig. 4B) . Indeed, the mSOD1-lysate treatment activated extracellular signalregulated kinase (ERK) 1/2 and cAMP responsive element binding protein (CREB) for a longer duration than did the control lysate treatment (Fig. 4C) . In contrast, CAPE rather decreased DAO expression (Fig. 4B) , and proinflammatory stimuli such as TNF-α or lipopolysaccharide elevated it without affecting ERK activation (Fig. S8 A and B) , suggesting proinflammatory factors potentially counteract repression of DAO caused by ERK activation. However, ERK-mediated down-regulation of DAO caused by mSOD1 lysate was far more potent than TNF-α-induced up-regulation (Fig. S8C) . In support of these findings, astrocytes with phosphorylated ERK1/2 were increased and did not show DAO activity in the spinal ventral horn of the mSOD1 mouse (Fig. 4 D and E) . Furthermore, incubation of primary cultured glia with PD98059 lowered the D-/L-serine ratio in the cultured medium (Fig. 4F) , suggesting that the MEK/ ERK signal is pivotal in DAO down-regulation.
In agreement with these results and the fact that stimulation of NMDAR activates the MAPK pathway, glutamate reduced DAO expression in primary cultured glia (Fig. S8D) . MK-801, a selective noncompetitive NMDAR antagonist, suppressed the decrease of DAO expression in primary cultured glia treated with the mSOD1 lysate, whereas 6,7-dinitroquinoxaline-2,3-dione (DNQX) (a non-NMDAR antagonist) or a peptide antagonist (WP9QY) for TNF receptor did not affect it (Fig.  4G) . The glial expressions of NMDARs were observed mainly in fibrous astrocytes in ventral white matter of control mice, whereas NMDARs were expressed also in reactive astrocytes in mSOD1 mice (Fig. S8 E-H) , supporting our view that glutamatergic action mediated by the NMDAR-MEK/ERK pathway seemed to be responsible for astrocytic DAO down-regulation in mSOD1 mice.
Discussion
Our data highlight the pathologic relevance of D-serine increase derived from reduced DAO activity in ALS. Using inbred mice lacking DAO activity, we provide evidence that loss of DAO activity triggers motoneuron degeneration. Moreover, using biochemical assays and sensitive quantitative methods to detect DAO activity and D-amino acids in the tissues, we have shown that (i) DAO activity is drastically suppressed in reactive astrocytes of the reticulospinal tract of mSOD1 mice, (ii) decreased degradation due to DAO inactivation contributes dominantly to the increase of D-serine, and (iii) the reduction of DAO activity is caused by progressive repression of DAO gene expression that mediates the NMDAR/ERK pathway.
In this study, we show that D-serine homeostasis is disrupted in the reticulospinal tract in mSOD1 mice (Fig. S9 A and B) . The reticulospinal tract is a major descending motor pathway in mammals and is assumed to be responsible for coordinated gross movements primarily of proximal muscles, whereas the corticospinal tract mediates fine movements, particularly of the hand (26) . The corticospinal tract is especially well developed in primates (26, 27) , and its sclerosis observed in the lateral columns of the spinal cord is a major characteristic of ALS. In nonprimate mammals including rodents, however, there are no direct cortico-motoneuronal connections. The reticulospinal tract, located in the anterior columns, primarily relays cortical input to spinal motoneurons (17, 28, 29) . Therefore, D-serine degradation by DAO in the reticulospinal tract is speculated to have a physiological significance in controlling motoneuronal excitability in rodents. Although, in humans, it is unknown whether DAO also exists in the reticulospinal tract or the other descending motor pathways, considering the R199W mutation in DAO is associated with familial ALS, D-serine homeostasis by DAO might also be physiologically important in the excitability of motoneurons in humans.
Because of the hindbrain-shifted distribution of DAO activity, physiological D-serine level in the spinal cord is strictly maintained at ≈1/50th of that in the forebrain (30) . In the mSOD1 mice, reduced DAO activity in the reactive astrocytes caused by repressions of its mRNA and protein expression contributes dominantly to the progressive D-serine increase and raises Dserine level by nearly three times at the end stage. Previously, we showed that proinflammatory factors also contribute to D-serine increase through SRR in activated microglia (10) . Although such and their ratio (D) in lumbar spinal cords of control and mSOD1 mice were quantified with 2D-HPLC at 3 mo (preonset stage around day 80, mSOD1, n = 6; control, n = 5), 4 mo (onset stage around day 120, mSOD1, n = 7; control, n = 7) and 5 mo (end stage around day 150, mSOD1, n = 7; control, n = 5) of age. P < 0.0001 (one-way ANOVA). Data are plotted as the mean ± SEM.
proinflammatory stimuli induce compensatory DAO expression in astrocytes (Fig. S8A) , the potent activation of ERK1/2 diminishes the action and rather results in reduction of DAO expression (Fig. S8C) . In ALS, excessive glutamate remains in the synaptic cleft due to loss of a glutamate transporter (EAAT2) (31) (32) (33) and is thought to activate ERK1/2 in reactive astrocytes through NMDARs but not AMPARs (Fig. 4G and  Fig. S9C ). The notion that activity of NMDARs affects DAO expression is supported by an in vivo study that systemic administration of MK-801 significantly up-regulates mRNA expression of DAO in the rat hindbrain (34) . Although research into astrocytic NMDARs is still controversial, some findings support the involvement of astrocytic NMDARs in rodent and human astrocytic cell signaling (35, 36) . Whether the NMDARs observed in reactive astrocytes in mSOD1 mice (Fig. S8G ) are functional and have pathological significance awaits future studies, but our findings shed light on the aberrant DAO regulation in mSOD1 mice.
DAO inactivation in mice results in pathological reflex (Fig. 1A) , spinal motoneuron degeneration (Fig. 1 B-D) , and abnormal locomotor activity (14) . Although more detailed studies are required for full characterization of the motor phenotype in the B6 DAO −/− mice, the B6 DAO −/− mice may bear a pathophysiological resemblance to the classical adult onset familial ALS associated with R199W-DAO, in which DAO activity is at trace level. Given that reduced DAO activity in the motoneuron input is crucial for motoneuron degeneration, undegraded D-amino acids might reasonably be associated with the mechanism of the degeneration. Moderate loss of DAO activity increases exclusively D-serine in the spinal cord, whereas its complete loss concomitantly affects D-alanine (Fig. S6A) . Both D-serine and D-alanine, albeit a lower affinity ligand than D-serine, bind to a coagonist site in NR1 subunit of NMDARs (37) ; therefore, the increase of both D-amino acids in the motoneuron input leads to elevating the occupancy of the coagonist site. Because coagonist binding is not only essential for NMDAR activity, but also increases the receptor's affinity for glutamate (38) and decreases its desensitization (39) , the high occupancy of the site is assumed to elevate motoneuron excitability. Thus, D-serine homeostasis in the spinal cord is considered to be physiologically important in motoneuronal excitability, and our findings give rise to the view that inactivity of DAO is pathologically relevant to the vulnerability of motoneurons to excitotoxicity in ALS.
The reduced DAO activity observed commonly in mSOD1 mice and familial ALS with R199W-DAO may not represent the whole ALS pathology because DAO activity is not suppressed in mTDP-43 mice. However, together with the findings in our earlier study that D-serine is increased in both sporadic and familial ALS with A4T-SOD1 (10), it is likely that a group of sporadic ALS and familial ALS with DAO and SOD1 mutations share the pathology of increased D-serine.
In conclusion, this study provides a unique understanding of the role of DAO and D-serine in motoneuron physiology as well as in ALS pathophysiology as a putative enhancer of motoneuron excitability. Our data also stress the potential use of regulators of DAO activity or D-serine antagonists as a therapeutic strategy in ALS.
Materials and Methods
Materials. For information about the materials used in this study, please refer to SI Materials and Methods.
Animals. All experiments on animals were carried out in accordance with institutional guidelines. The study protocol was approved by the Animal Experiment Committee of KEIO University. Animals used in this study are detailed in SI Materials and Methods.
Histological Analysis. Histological analysis is detailed in SI Materials and Methods. Primary Culture of Glia. Primary cultured glia were prepared from cerebellum of E16 mouse embryos and treated with various inhibitors or spinal cord lysate or both. Please refer to SI Materials and Methods for additional details.
Western Blot Analysis. Western blot analysis is detailed in SI Materials and Methods.
Statistical Analysis. All values in the text and figures of this study indicate means ± SEM. Statistical analyses for the experiments were performed with two-tailed Student's t test or one-way ANOVA followed by Tukey's multiple comparison test, in which P < 0.05 was assessed as significant. All analyses were performed by using Prism 5 (GraphPad Software).
